121 related articles for article (PubMed ID: 7535938)
1. The utility of salivary amylase as an evaluation of M3 muscarinic agonist activity in Alzheimer's disease.
Sramek JJ; Cutler NR; Hurley DJ; Seifert RD
Prog Neuropsychopharmacol Biol Psychiatry; 1995 Jan; 19(1):85-91. PubMed ID: 7535938
[TBL] [Abstract][Full Text] [Related]
2. The safety and tolerance of xanomeline tartrate in patients with Alzheimer's disease.
Sramek JJ; Hurley DJ; Wardle TS; Satterwhite JH; Hourani J; Dies F; Cutler NR
J Clin Pharmacol; 1995 Aug; 35(8):800-6. PubMed ID: 8522637
[TBL] [Abstract][Full Text] [Related]
3. The selective muscarinic agonist xanomeline improves both the cognitive deficits and behavioral symptoms of Alzheimer disease.
Bodick NC; Offen WW; Shannon HE; Satterwhite J; Lucas R; van Lier R; Paul SM
Alzheimer Dis Assoc Disord; 1997; 11 Suppl 4():S16-22. PubMed ID: 9339268
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of xanomeline in Alzheimer disease: cognitive improvement measured using the Computerized Neuropsychological Test Battery (CNTB).
Veroff AE; Bodick NC; Offen WW; Sramek JJ; Cutler NR
Alzheimer Dis Assoc Disord; 1998 Dec; 12(4):304-12. PubMed ID: 9876958
[TBL] [Abstract][Full Text] [Related]
5. Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease.
Bodick NC; Offen WW; Levey AI; Cutler NR; Gauthier SG; Satlin A; Shannon HE; Tollefson GD; Rasmussen K; Bymaster FP; Hurley DJ; Potter WZ; Paul SM
Arch Neurol; 1997 Apr; 54(4):465-73. PubMed ID: 9109749
[TBL] [Abstract][Full Text] [Related]
6. Effects of central muscarinic-1 receptor stimulation on blood pressure regulation.
Medina A; Bodick N; Goldberger AL; Mac Mahon M; Lipsitz LA
Hypertension; 1997 Mar; 29(3):828-34. PubMed ID: 9052903
[TBL] [Abstract][Full Text] [Related]
7. A bridging study of LU 25-109 in patients with probable Alzheimer's disease.
Sramek JJ; Forrest M; Mengel H; Jhee SS; Hourani J; Cutler NR
Life Sci; 1998; 62(3):195-202. PubMed ID: 9488097
[TBL] [Abstract][Full Text] [Related]
8. Xanomeline and the antipsychotic potential of muscarinic receptor subtype selective agonists.
Mirza NR; Peters D; Sparks RG
CNS Drug Rev; 2003; 9(2):159-86. PubMed ID: 12847557
[TBL] [Abstract][Full Text] [Related]
9. Brain proton magnetic resonance spectroscopy in Alzheimer disease: changes after treatment with xanomeline.
Frederick Bd; Satlin A; Wald LL; Hennen J; Bodick N; Renshaw PF
Am J Geriatr Psychiatry; 2002; 10(1):81-8. PubMed ID: 11790638
[TBL] [Abstract][Full Text] [Related]
10. Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia.
Shekhar A; Potter WZ; Lightfoot J; Lienemann J; Dubé S; Mallinckrodt C; Bymaster FP; McKinzie DL; Felder CC
Am J Psychiatry; 2008 Aug; 165(8):1033-9. PubMed ID: 18593778
[TBL] [Abstract][Full Text] [Related]
11. The muscarinic M1/M4 receptor agonist xanomeline exhibits antipsychotic-like activity in Cebus apella monkeys.
Andersen MB; Fink-Jensen A; Peacock L; Gerlach J; Bymaster F; Lundbaek JA; Werge T
Neuropsychopharmacology; 2003 Jun; 28(6):1168-75. PubMed ID: 12700711
[TBL] [Abstract][Full Text] [Related]
12. Lu 25-109, a muscarinic agonist, fails to improve cognition in Alzheimer's disease. Lu25-109 Study Group.
Thal LJ; Forrest M; Loft H; Mengel H
Neurology; 2000 Jan; 54(2):421-6. PubMed ID: 10668706
[TBL] [Abstract][Full Text] [Related]
13. Brain proton magnetic resonance spectroscopy (1H-MRS) in Alzheimer's disease: changes after treatment with xanomeline, an M1 selective cholinergic agonist.
Satlin A; Bodick N; Offen WW; Renshaw PF
Am J Psychiatry; 1997 Oct; 154(10):1459-61. PubMed ID: 9326834
[TBL] [Abstract][Full Text] [Related]
14. M1 agonists for the treatment of Alzheimer's disease. Novel properties and clinical update.
Fisher A; Heldman E; Gurwitz D; Haring R; Karton Y; Meshulam H; Pittel Z; Marciano D; Brandeis R; Sadot E; Barg Y; Pinkas-Kramarski R; Vogel Z; Ginzburg I; Treves TA; Verchovsky R; Klimowsky S; Korczyn AD
Ann N Y Acad Sci; 1996 Jan; 777():189-96. PubMed ID: 8624083
[TBL] [Abstract][Full Text] [Related]
15. ABT-126 monotherapy in mild-to-moderate Alzheimer's dementia: randomized double-blind, placebo and active controlled adaptive trial and open-label extension.
Gault LM; Lenz RA; Ritchie CW; Meier A; Othman AA; Tang Q; Berry S; Pritchett Y; Robieson WZ
Alzheimers Res Ther; 2016 Oct; 8(1):44. PubMed ID: 27756421
[TBL] [Abstract][Full Text] [Related]
16. Attenuation of neurodegenerative phenotypes in Alzheimer-like presenilin 1/presenilin 2 conditional double knockout mice by EUK1001, a promising derivative of xanomeline.
Wang D; Yang L; Su J; Niu Y; Lei X; Xiong J; Cao X; Hu Y; Mei B; Hu JF
Biochem Biophys Res Commun; 2011 Jul; 410(2):229-34. PubMed ID: 21651893
[TBL] [Abstract][Full Text] [Related]
17. Phase I clinical trials with WAL 2014, a new muscarinic agonist for the treatment of Alzheimer's disease.
Adamus WS; Leonard JP; Tröger W
Life Sci; 1995; 56(11-12):883-90. PubMed ID: 10188789
[TBL] [Abstract][Full Text] [Related]
18. The utility of muscarinic agonists in the treatment of Alzheimer's disease.
Messer WS
J Mol Neurosci; 2002; 19(1-2):187-93. PubMed ID: 12212779
[TBL] [Abstract][Full Text] [Related]
19. [Selective M1 muscarinic agonists: failure of therapeutic strategy against Alzheimer's disease or inappropriate tactics?].
Vamvakidès A
Ann Pharm Fr; 2003 May; 61(3):207-10. PubMed ID: 12714934
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological approaches to targeting muscarinic acetylcholine receptors.
Matera C; Tata AM
Recent Pat CNS Drug Discov; 2014; 9(2):85-100. PubMed ID: 25413004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
